In this patient population, BRAF p.V600E was only significantly associated with PTC subtype and follow-up time, but not with TN category, tumor size, nodal disease burden, tumor multifocality, extrathyroidal extension, treatment, recurrence, or mortality (Table 1). The gene discussed is BRAF; the disease is neoplasm.